Charles W. Flexner, MD

CRS:

JHU

Role:

Investigators

Position:

Site Leader

Email:

flex@jhmi.edu

Charles W. Flexner, M.D., is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health. Dr. Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. His scientific contributions include work on the important roles of pharmacokinetic enhancement, adherence, and dosing frequency in the long-term management of HIV/AIDS. He has published extensively on anti-infective drug transport and metabolism, and metabolic drug interactions. Dr. Flexner is currently the Deputy Director of the Institute for Clinical and Translational Research at Johns Hopkins, where he serves as Program Director for Clinical Research Units. He also serves as Associate Vice-Chair for Academic Fellowship Programs in the Department of Medicine, and Associate Director of the Graduate Training Programs in Clinical Investigation of the Johns Hopkins University School of Medicine and Bloomberg School of Public Health. Dr. Flexner is the Co-Principal Investigator of the Johns Hopkins University Baltimore-Washington-India Clinical Trials Unit (BWI CTU) supported by the NIH, and was Chair of the AIDS Clinical Trials Group (ACTG) Translational Research and Drug Development (TRADD) Committee from 2009-2011. Dr. Flexner served as President of the American Federation for Medical Research (AFMR) in 1999-2000, and was President of the AFMR Foundation from 2001-2002. He is a member of the editorial board of 10 scientific journals. He currently serves as a consultant to the Bill and Melinda Gates Foundation and the Clinton Health Access Initiative, and served as a consultant on FDA reform to the United States House of Representatives.

  • Member, Clinical Pharmacology Advisory Group of the Laboratory Steering Committee (2011-Present)
  • Non-Voting Member, Antiretroviral Therapy Strategies Subcommittee of the SASC (Dec 2016)
  • Chair, ACTG Antiretroviral Therapy Strategies TSG (Dec 2018-Nov2020)
  • Co-chair ACTG 5211
  • Protocol Pharmacologist for ACTG 5211, ACTG 5258, and ACTG 5336

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More